Global Oncolytic Virus Immunotherapy Market Assessment, With Major Companies Analysis, Regional Analysis, Breakdown Data by Application/Type
- Published Date: 2020-12-28
- Report ID: 35696
- Pages: 96
-
Format:
Summary
This study analysis was given on a worldwide scale, for instance, present and historical Oncolytic Virus Immunotherapy growth analysis, competitive analysis, and also the growth prospects of the major regions. The report gives an exhaustive investigation of this market at country & regional levels, and provides an analysis of the industry trends in each of the sub-segments, from production, revenue and consumption. A quantitative and qualitative analysis of the main players in related regions is introduced, from the perspective of Oncolytic Virus Immunotherapy production, Oncolytic Virus Immunotherapy revenue, Oncolytic Virus Immunotherapy consumption and Oncolytic Virus Immunotherapy price.
According to the current situation, the official counts of cases and deaths from COVID-19 have passed 4,000,000 and 280,000 at the time of this report. Many government announced a plan on reopening the national economy, but many countries are still at the stage of rising. Prudent Markets published a report for global Oncolytic Virus Immunotherapy market in this environment.
In terms of revenue, this research report indicated that the global Oncolytic Virus Immunotherapy market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Oncolytic Virus Immunotherapy industry comprises of Asia, North America, South America, Middle East and Africa, Europe, with the production and revenue data in each of the sub-segments.
The BioVex Inc. aims at producing XX Oncolytic Virus Immunotherapy in 2020, with XX % production to take place in global market, Cell Genesys accounts for a volume share of XX %.
At the upcoming analysis, this report discusses industrial policy, economic environment, in addition to the COVID-19 impact and cost structures of the industry. And this report encompasses the fundamental dynamics of the market which include drivers, opportunities, and challenges faced by the industry. Additionally, this report showed a keen market study of the main consumers, raw material manufacturers and distributors, etc.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Oncolytic Virus Immunotherapy Market by Prudent Markets Include
NorthAmerica
Asia
Europe
Middle East & Africa
South America
Competitive Analysis; Who are the Major Players in Oncolytic Virus Immunotherapy Market
BioVex Inc.
Cell Genesys
Crusade Laboratories
Genelux Corporation
Jennerex Biotherapeutics
Lokon Pharma
Merck
MultiVir
Oncolys BioPharma
Oncolytics Biotech
Oncos Therapeutics (Targovax)
PsiOxus Therapeutics
Shanghai Sunway Biotech
Takara Bio
VCN Biosciences
ViroTarg
Vyriad
Major Type of Oncolytic Virus Immunotherapy Covered in Prudent Markets report:
Herpes Simplex Virus
Vaccinia Virus
Adenovirus
Reovirus
Others
Application Segments Covered in Prudent Markets Market
Melanoma
Non-small Cell Lung Cancer [NSCLC]
Pancreatic Cancer
Breast Cancer
Others
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Oncolytic Virus Immunotherapy Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 Herpes Simplex Virus -Product Introduction and Major Manufacturers
1.1.2 Vaccinia Virus -Product Introduction and Major Manufacturers
1.1.3 Adenovirus -Product Introduction and Major Manufacturers
1.1.4 Reovirus -Product Introduction and Major Manufacturers
1.1.5 Others -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Regional Market
2.1 Regional Market Share in Terms of Production (2019-2026)
2.2 Regional Market Share in Terms of Revenue (2019-2026)
2.3 Regional Market Share in Terms of Consumption (2019-2026)
3 Global Oncolytic Virus Immunotherapy Market Assessment by Type
3.1 Global Oncolytic Virus Immunotherapy Production by Type (2015-2026)
3.2 Global Oncolytic Virus Immunotherapy Revenue by Type (2015-2026)
3.3 North America Oncolytic Virus Immunotherapy Production and Revenue by Type (2015-2026)
3.4 Asia Oncolytic Virus Immunotherapy Production and Revenue by Type (2015-2026)
3.5 Europe Oncolytic Virus Immunotherapy Production and Revenue by Type (2015-2026)
3.6 Middle East & Africa Oncolytic Virus Immunotherapy Production and Revenue by Type (2015-2026)
3.7 South America Oncolytic Virus Immunotherapy Production and Revenue by Type (2015-2026)
4 Global Oncolytic Virus Immunotherapy Market Assessment by Application
4.1 Historical & Forecast Global Oncolytic Virus Immunotherapy Consumption, Different Application Field (2015-2026)
4.2 Historical & Forecast North America Oncolytic Virus Immunotherapy Consumption, Different Application Field (2015-2026)
4.3 Historical & Forecast Asia Oncolytic Virus Immunotherapy Consumption, Different Application Field (2015-2026)
4.4 Historical & Forecast Europe Oncolytic Virus Immunotherapy Consumption, Different Application Field (2015-2026)
4.5 Historical & Forecast Middle East & Africa Oncolytic Virus Immunotherapy Consumption, Different Application Field (2015-2026)
4.6 Historical & Forecast South America Oncolytic Virus Immunotherapy Consumption, Different Application Field (2015-2026)
5 North America
5.1 US Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
5.2 Canada Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
5.3 Mexico Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
6 Asia
6.1 China Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
6.2 Japan Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
6.3 India Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
6.4 Korea Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
6.5 Southeat Asia Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
7 Europe
7.1 Germany Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
7.2 UK Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
7.3 France Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
7.4 Russia Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
7.5 Italy Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
8 Middle East and Africa
8.1 Saudi Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
8.2 UAE Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
8.3 Egypt Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
8.4 Nigeria Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
8.5 South Africa Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
9 South America
9.1 Brazil Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
9.2 Argentina Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
9.3 Colombia Oncolytic Virus Immunotherapy Capacity, Production, Consumption and Proportion of Products Sold (2015-2026)
10 Global Oncolytic Virus Immunotherapy Average Price Trend
10.1 Market Price for Each Type of Oncolytic Virus Immunotherapy in North America (2015-2026)
10.2 Market Price for Each Type of Oncolytic Virus Immunotherapy in Asia (2015-2026)
10.3 Market Price for Each Type of Oncolytic Virus Immunotherapy in Europe (2015-2026)
10.4 Market Price for Each Type of Oncolytic Virus Immunotherapy in Middle East & Africa (2015-2026)
10.5 Market Price for Each Type of Oncolytic Virus Immunotherapy in South America (2015-2026)
11 Value Chain (Impact of COVID-19)
11.1 Oncolytic Virus Immunotherapy Value Chain Analysis
11.1.1 Upstream
11.1.2 Downstream
11.2 COVID-19 Impact on Oncolytic Virus Immunotherapy Industry
11.2.1 Industrial Policy Issued Under the Epidemic Situation
11.3 Cost-Under the Epidemic Situation
11.3.1 Cost of Raw Material
11.4 Channel Analysis
11.4.1 Distribution Channel-Under the Epidemic Situation
11.4.2 Distributors
12 Oncolytic Virus Immunotherapy Competitive Analysis
12.1 BioVex Inc.
12.1.1 BioVex Inc. Company Profiles
12.1.2 BioVex Inc. Product Introduction
12.1.3 BioVex Inc. Oncolytic Virus Immunotherapy Production, Revenue (2015-2020)
12.1.4 SWOT Analysis
12.2 Cell Genesys
12.2.1 Cell Genesys Company Profiles
12.2.2 Cell Genesys Product Introduction
12.2.3 Cell Genesys Oncolytic Virus Immunotherapy Production, Revenue (2015-2020)
12.2.4 SWOT Analysis
12.3 Crusade Laboratories
12.3.1 Crusade Laboratories Company Profiles
12.3.2 Crusade Laboratories Product Introduction
12.3.3 Crusade Laboratories Oncolytic Virus Immunotherapy Production, Revenue (2015-2020)
12.3.4 SWOT Analysis
12.4 Genelux Corporation
12.4.1 Genelux Corporation Company Profiles
12.4.2 Genelux Corporation Product Introduction
12.4.3 Genelux Corporation Oncolytic Virus Immunotherapy Production, Revenue (2015-2020)
12.4.4 SWOT Analysis
12.5 Oncolys BioPharma
12.5.1 Jennerex Biotherapeutics Company Profiles
12.5.2 Jennerex Biotherapeutics Product Introduction
12.5.3 Jennerex Biotherapeutics Oncolytic Virus Immunotherapy Production, Revenue (2015-2020)
12.5.4 SWOT Analysis
12.6 Lokon Pharma
12.6.1 Lokon Pharma Company Profiles
12.6.2 Lokon Pharma Product Introduction
12.6.3 Lokon Pharma Oncolytic Virus Immunotherapy Production, Revenue (2015-2020)
12.6.4 SWOT Analysis
12.7 Merck
12.7.1 Merck Company Profiles
12.7.2 Merck Product Introduction
12.7.3 Merck Oncolytic Virus Immunotherapy Production, Revenue (2015-2020)
12.7.4 SWOT Analysis
12.8 MultiVir
12.8.1 MultiVir Company Profiles
12.8.2 MultiVir Product Introduction
12.8.3 MultiVir Oncolytic Virus Immunotherapy Production, Revenue (2015-2020)
12.8.4 SWOT Analysis
12.9 Oncolys BioPharma
12.9.1 Oncolys BioPharma Company Profiles
12.9.2 Oncolys BioPharma Product Introduction
12.9.3 Oncolys BioPharma Oncolytic Virus Immunotherapy Production, Revenue (2015-2020)
12.9.4 SWOT Analysis
12.10 Oncolytics Biotech
12.10.1 Oncolytics Biotech Company Profiles
12.10.2 Oncolytics Biotech Product Introduction
12.10.3 Oncolytics Biotech Oncolytic Virus Immunotherapy Production, Revenue (2015-2020)
12.10.4 SWOT Analysis
12.11 Oncos Therapeutics (Targovax)
12.12 PsiOxus Therapeutics
12.13 Shanghai Sunway Biotech
12.14 Takara Bio
12.15 VCN Biosciences
12.16 ViroTarg
12.17 Vyriad
13 Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
